“Afrigen Biologics has earned Good Manufacturing Practice (GMP) certification from the South African Health Products Regulatory Authority (SAHPRA), validating Africa’s first fully integrated mRNA manufacturing facility. This breakthrough strengthens Africa’s ability to produce investigational biological products for clinical trials, reduces reliance on imported vaccines, and enhances pandemic preparedness.”
South Africa has taken a decisive step into the future of biotechnology with Afrigen Biologics achieving GMP certification for its Cape Town-based mRNA manufacturing facility. This milestone is not just a national triumph but a continental breakthrough, symbolizing Africa’s growing capacity to produce advanced vaccines and biologics. GMP certification validates compliance with global safety and quality standards, enabling Afrigen to manufacture investigational biological products for Phase I and II clinical trials.
Why GMP Certification Matters
- Global Standards Compliance: GMP certification ensures adherence to internationally recognized safety and quality benchmarks.
- Clinical Trial Readiness: Afrigen can now manufacture investigational biological products for clinical trials, a critical step toward vaccine innovation.
- Health Sovereignty: By reducing reliance on imports, South Africa strengthens its ability to respond to pandemics and supply vaccines locally.
Lessons from COVID-19
The COVID-19 pandemic exposed Africa’s vulnerability in vaccine access. Wealthy nations secured doses early, while African countries faced delays and shortages. Afrigen’s facility directly addresses this inequity, ensuring that future pandemics do not leave Africa dependent on external suppliers.
Afrigen’s Journey
- 2022–2023: Conceptualization of the mRNA Technology Transfer Programme, co-led by the World Health Organization (WHO) and the Medicines Patent Pool (MPP).
- 2024–2025: Infrastructure development, recruitment of scientists, and establishment of pilot production lines.
- 2026: GMP certification achieved, marking readiness for clinical trial material production.
Strategic Importance
Afrigen’s facility is more than a national achievement—it is a continental asset.
- Pandemic Preparedness: Rapid response capability for emerging infectious diseases.
- Regional Manufacturing Hub: A platform for vaccine production across Africa.
- Innovation Ecosystem: Collaboration between academia, government, and industry to advance biotechnology.
Voices of Leadership
Prof. Petro Terblanche, CEO of Afrigen, emphasized: “This certification is a tribute to the extraordinary commitment of our team. We are ready to support clinical trial production and contribute meaningfully to vaccine development.”
Broader Implications for Africa
Afrigen’s GMP certification signals a shift in Africa’s biotech landscape. It demonstrates that the continent can not only participate in but also lead global innovation in vaccine development. This achievement is expected to inspire similar initiatives across Africa, fostering a new era of biotech independence.
Economic and Social Impact
- Job Creation: The facility has already created hundreds of skilled jobs for scientists, engineers, and technicians.
- Capacity Building: Training programs are being established to develop the next generation of African biotech professionals.
- Healthcare Access: Local vaccine production will reduce costs and improve access for millions of Africans.
Conclusion
Afrigen Biologics’ GMP certification marks a turning point in Africa’s biotechnology journey. It represents resilience, innovation, and sovereignty in healthcare. As South Africa leads the way, the rest of the continent stands to benefit from a stronger, more independent biotech ecosystem.
